Literature DB >> 29285381

Effect of biology on the outcome of female melanoma patients.

Kayhan Erturk1, Faruk Tas1.   

Abstract

The aim of the present study was to investigate plausible explanations for the favorable outcome of female melanoma patients and determine the effect of biology on this outcome. Data from 1,169 cutaneous melanoma patients were retrospectively analyzed. Cox proportional hazards models were used and the confounding factors on the survival difference were analyzed by a forward step multivariate modification method. The majority of the factors contributing to poor prognosis were significantly more pronounced in male melanoma patients. After the survival advantage of female patients (P=0.0001 on univariate analysis) was confounded (P=0.708 on multivariate analysis) following adjustment for the prognostic factors, two factors (neurotropism and vertical growth phase) were identified as the confounders, and this effect was attributed to the small number of patients in the groups of these two variables. The already known female advantage in melanoma survival was not affected by other prognostic factors, and female sex remained an independent predictor of good survival in melanoma. This sex-related independent survival advantage was attributed to a biological characteristic that has not yet been fully elucidated, but may be more closely associated with host-related rather than melanoma-related factors.

Entities:  

Keywords:  biology; melanoma; sex; survival

Year:  2017        PMID: 29285381      PMCID: PMC5740849          DOI: 10.3892/mco.2017.1446

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  24 in total

1.  Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.

Authors:  John F Thompson; Seng-Jaw Soong; Charles M Balch; Jeffrey E Gershenwald; Shouluan Ding; Daniel G Coit; Keith T Flaherty; Phyllis A Gimotty; Timothy Johnson; Marcella M Johnson; Stanley P Leong; Merrick I Ross; David R Byrd; Natale Cascinelli; Alistair J Cochran; Alexander M Eggermont; Kelly M McMasters; Martin C Mihm; Donald L Morton; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Gender-related differences in outcome for melanoma patients.

Authors:  Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

3.  Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas.

Authors:  Wendy Liu; John P Dowling; William K Murray; Grant A McArthur; John F Thompson; Rory Wolfe; John W Kelly
Journal:  Arch Dermatol       Date:  2006-12

4.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Authors:  Georgina V Long; Alexander M Menzies; Adnan M Nagrial; Lauren E Haydu; Anne L Hamilton; Graham J Mann; T Michael Hughes; John F Thompson; Richard A Scolyer; Richard F Kefford
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

5.  Melanoma and tumor thickness: challenges of early diagnosis.

Authors:  M A Richard; J J Grob; M F Avril; M Delaunay; X Thirion; P Wolkenstein; P Souteyrand; B Dreno; J J Bonerandi; S Dalac; L Machet; J C Guillaume; J Chevrant-Breton; C Vilmer; F Aubin; B Guillot; M Beylot-Barry; C Lok; N Raison-Peyron; P Chemaly
Journal:  Arch Dermatol       Date:  1999-03

6.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

Review 7.  Gender and survival in malignant tumours.

Authors:  R Molife; P Lorigan; S MacNeil
Journal:  Cancer Treat Rev       Date:  2001-08       Impact factor: 12.111

Review 8.  Use of tamoxifen in the treatment of malignant melanoma.

Authors:  Marko B Lens; Tony Reiman; Amna F Husain
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

Review 9.  The natural course of cutaneous melanoma.

Authors:  Ulrike Leiter; Friedegund Meier; Birgit Schittek; Claus Garbe
Journal:  J Surg Oncol       Date:  2004-07-01       Impact factor: 3.454

10.  Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.

Authors:  Arjen Joosse; Sandra Collette; Stefan Suciu; Tamar Nijsten; Poulam M Patel; Ulrich Keilholz; Alexander M M Eggermont; Jan Willem W Coebergh; Esther de Vries
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.